Browse the evidence

The pathophysiological link between NAFLD and CVD is driven by systemic inflammation, endothelial dysfunction, and atherogenic dyslipidemia (specifically high ApoC3 and small dense LDL) resulting from hepatic fat accumulation and insulin resistance.

Understanding that liver fat drives heart risk through inflammation and bad cholesterol helps explain why lifestyle changes (diet/exercise) that reduce liver fat also protect the heart. It is not just about weight loss, but improving metabolic health.

Gestational diabetes mellitus (GDM) is the most prominent independent risk factor for the progression to type 2 diabetes in women, increasing the relative risk by approximately 8.3-fold.

If you had gestational diabetes, your risk of developing type 2 diabetes is over 8 times higher than women who did not. This risk persists for years. You need lifelong, regular glucose monitoring and lifestyle interventions, as standard postpartum care often neglects this long-term metabolic risk.

Rare and low-frequency coding genetic variants in genes such as MC4R, GIPR, and KSR2 are significantly associated with Body Mass Index (BMI), with effect sizes approximately ten times larger than those of common variants.

Your genetics play a role in your weight, but for most people, common lifestyle factors (diet, activity) are far more impactful than rare genetic mutations. If you have a known high-impact mutation like MC4R p.Tyr35Ter, you may need more aggressive or specialized medical interventions, but for the general population, focusing on energy balance remains the most effective strategy.

Systemic and hepatic insulin resistance is the central pathophysiological mechanism driving the development and progression of metabolic dysfunction-associated fatty liver disease (MAFLD).

Focus on improving insulin sensitivity through weight management, physical activity, and dietary quality. Since insulin resistance is the root cause of MAFLD, interventions that lower insulin levels and improve glucose handling (like exercise and reducing refined carbohydrates) are the most effective way to prevent or reverse liver fat accumulation.

Insulin resistance in adipose tissue leads to increased free fatty acid (FFA) release, which drives hepatic fat accumulation and inflammation.

Reducing visceral fat through caloric deficit and exercise improves adipose tissue insulin sensitivity, thereby reducing the flood of FFAs to the liver and lowering liver fat.

Black adults experience higher rates of short sleep and poor sleep quality compared to Whites, and this disparity is exacerbated by socioeconomic stressors and unique psychosocial stressors like 'John Henryism'.

If you are Black, you may face unique stressors that disrupt sleep. Recognize that your sleep difficulties may be linked to systemic stress and not just personal habits. Seek support for stress management and prioritize rest as a health necessity.

Pharmacological interventions for diabetes prevention are effective during active treatment but lose their efficacy immediately upon discontinuation, indicating they do not alter the underlying pathophysiology of insulin resistance or beta-cell dysfunction.

Medications can effectively prevent diabetes while you are taking them, but they do not provide long-term protection once you stop. If you discontinue medication, your risk returns to baseline. Therefore, medications are not a substitute for sustainable lifestyle changes if you plan to stop treatment.

Accelerometer-derived measures of sleep duration and quality are heritable and genetically distinct from self-reported measures, with specific genetic variants (e.g., PDE11A, MEIS1) influencing sleep traits.

Use objective sleep tracking (accelerometers) to get a more accurate picture of your sleep genetics and quality, as self-reports may be biased. Focus on identifying specific sleep issues (duration, efficiency) rather than just feeling rested.

Obesity causes hypertension through multiple mechanisms including SNS overactivation, RAAS stimulation, leptin resistance, insulin resistance, and mechanical renal compression.

High blood pressure in obese individuals is not just about volume; it's driven by overactive nerves, hormones like leptin and insulin, and physical pressure on the kidneys. Treating the obesity addresses these root causes.

Macrophage accumulation and polarization towards a proinflammatory (M1-like) state in adipose tissue is the dominant mechanism driving insulin resistance in obesity.

Your fat cells aren't just storage; they recruit immune cells called macrophages when overfilled. These macrophages release inflammatory signals that block insulin. Reducing this inflammation, potentially through weight loss or anti-inflammatory strategies, is crucial for fixing insulin resistance.

AgRP neurons promote feeding and inhibit energy expenditure by antagonizing MC4R, and their activity is increased during fasting/starvation.

During fasting, your body activates AgRP neurons to drive hunger and conserve energy. This is a normal survival mechanism. Understanding this helps explain why hunger increases when you restrict calories.

Semaglutide (both oral and subcutaneous formulations) is associated with a high incidence of mild-to-moderate, transient gastrointestinal adverse effects (nausea, vomiting, diarrhea), which are dose-dependent and time-dependent, occurring primarily during the initial 8-12 weeks of treatment.

If you start semaglutide, expect some nausea, vomiting, or diarrhea, especially in the first few months. This is common and usually gets better. To minimize this, start with the lowest dose and follow the doctor's schedule for increasing it slowly. Eat smaller, slower meals and avoid fatty foods. If you take the oral version, take it on an empty stomach with a small sip of water, waiting 30 minutes before eating or drinking anything else.

Semaglutide does not significantly increase the risk of hypoglycemia in patients not using concomitant insulin or sulfonylureas, due to its glucose-dependent mechanism of action.

You don't need to worry about your blood sugar dropping dangerously low while taking semaglutide by itself. It works gently with your body's natural processes. However, if you are also taking insulin or sulfonylureas, your risk of low blood sugar increases, so your doctor may lower the dose of those other medications.

Adiponectin, secreted by healthy PVAT, acts as a vasodilator by activating AdipoR1 receptors, stimulating AMPK and eNOS to produce nitric oxide, thereby lowering blood pressure and improving insulin sensitivity.

Maintaining healthy adipose tissue function is crucial. While direct adiponectin supplementation is not discussed as a standard therapy, lifestyle interventions that improve adipose tissue health (like exercise and weight loss) naturally boost adiponectin levels, aiding blood pressure control and insulin sensitivity.

Testosterone treatment in older men with low testosterone increases volumetric bone mineral density and estimated bone strength, but does not significantly improve areal bone mineral density.

If you are an older man with confirmed low testosterone, testosterone therapy can significantly improve your bone density and bone strength, particularly in the spine. The treatment involves daily application of a gel, with dose adjustments to keep levels in the normal range for young men. While long-term safety requires more data, this study found no increase in cardiovascular or prostate issues over one year.

Insulin resistance is a central mechanism in Metabolic Syndrome, driven by impaired insulin signaling pathways (PI3K/Akt) and exacerbated by factors like saturated fatty acids, oxidative stress, and chronic inflammation.

Metabolic Syndrome is largely driven by insulin resistance, where your body's cells don't respond well to insulin. This leads to high blood sugar, fat storage, and other issues. Managing this involves addressing the root causes of insulin resistance through diet, exercise, and weight management.

Metabolic syndrome is fundamentally a chronic inflammatory state driven by immune system deregulation, specifically involving M1 macrophages and pro-inflammatory cytokines (TNF-alpha, IL-1beta) originating from adipose tissue, liver, and intestine.

Think of your fat tissue not just as stored energy, but as an active organ that sends out distress signals (inflammation) when it's overstuffed. These signals damage your blood vessels and block insulin. Managing your weight and staying active directly calms this immune response, protecting your heart and metabolic health.

Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea) compared to placebo and basal insulin, which can lead to treatment discontinuation.

Tirzepatide often causes stomach problems like nausea, vomiting, and diarrhea, especially at higher doses (10mg and 15mg). These side effects are more common than with placebo or basal insulin and can cause some people to stop taking the medication. Starting at a lower dose and increasing slowly may help.

Intensive glycemic control (targeting HbA1c <6.0-6.5%) slows the progression of microvascular complications (retinopathy, nephropathy, neuropathy) in type 2 diabetes, but does not significantly reduce macrovascular events within the first 3-5 years of treatment.

For Type 2 Diabetes, keeping blood sugar very low (HbA1c <6.5%) protects your eyes, kidneys, and nerves, but this protection takes years to show up in heart health. Be aware that aggressive sugar lowering can increase the risk of dangerous low blood sugar episodes, so the target must be balanced carefully with your doctor.

Manipulating dietary Glycemic Index (GI) or Glycemic Load (GL) does not provide a significant benefit for weight loss, satiety, or cardiometabolic risk factors compared to isocaloric high-GI diets when fiber and energy intake are controlled.

Stop obsessing over the Glycemic Index for weight loss or health. The science shows that swapping high-GI foods for low-GI ones does not help you lose more weight or feel fuller, provided you eat the same amount of calories and fiber. Focus on eating whole foods, vegetables, and fiber-rich carbohydrates instead of calculating GI numbers. If you enjoy high-GI foods like white rice or potatoes, include them as part of a balanced meal with fiber and protein; they will not sabotage your health goals.

Women with diabetes have a 30% greater excess risk of cardiovascular disease (CVD) mortality compared to men with diabetes, driven largely by a higher risk of coronary heart disease (CHD) mortality.

Women with diabetes face a 30% higher relative risk of dying from heart disease than men with diabetes. This underscores the importance of rigorous cardiovascular monitoring and prevention for women, potentially requiring more aggressive management than standard protocols might imply.

Metformin blunts increases in thigh muscle area and density resulting from progressive resistance training in older adults.

Metformin reduces the structural improvements (area and density) you get from weight training. This might be due to increased fat inside muscle cells. Talk to your doctor about your medication if muscle growth is a priority.

Metformin does not affect muscle fiber hypertrophy (cross-sectional area) or satellite cell abundance in response to progressive resistance training in older adults.

While metformin reduces overall muscle size, it doesn't seem to stop individual muscle fibers from growing. The issue may be related to fat content or other factors, not the fiber size itself.

Insulin resistance is a key pathophysiological factor in NAFLD, creating a bidirectional relationship where insulin resistance leads to liver fat accumulation and liver fat accumulation worsens insulin sensitivity.

Focus on improving insulin sensitivity. This involves managing weight, reducing refined carbs, and regular exercise. It helps both the liver and metabolic health.